July 1, 2015
Obese children with nonalcoholic fatty liver disease treated with omega-3 fatty acids, docosahexaenoic acid and eicosapentaenoic acid, had reduced aspartate aminotransferase and gamma-glutamyl transpeptidase levels compared with children treated with placebo, according to data published in The Journal of Pediatrics.
Researchers randomly assigned 76 obese or overweight children to receive between 450 and 1,300 mg per day of docosahexaenoic and eicosapentaenoic acids or omega-6 sunflower oil, which served as placebo, for 24 weeks. The primary goal of the trial was to determine the number of patients with decreased alanine aminotransferase levels at least 0.3 times the upper limit of normal post-treatment. Secondary goals included alterations in liver function tests, liver hyperechogenicity, insulin resistance and other metabolic markers after 6 months of intervention, according to the research. The median age of the patients was 13 years and a total of 64 children completed the trial and were included in the final analyses.